Nucleos(t)ide therapy

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Hepatitis B

Phase 2

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

CompletedNCT04449029

GlaxoSmithKlineHepatitis B

Start: 2020-07-27End: 2022-03-18Updated: 2023-05-16

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

CompletedNCT04544956

GlaxoSmithKlineHepatitis B

Start: 2020-10-06End: 2023-11-30Updated: 2025-07-15

Related Papers

Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B.

2026-01-14

Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study).

2025-10-032 citations

Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs

Clinical Pharmacology in Drug Development2025-02-143 citations

Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies.

2024-05-252 citations

Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report

Zeitschrift für Gastroenterologie2024-01-011 citations

B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection

Advances in Therapy2023-07-012 citations

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

New England Journal of Medicine2022-11-08229 citations